Tonix Pharmaceuticals Announces Results Of Pre-IND Meeting With FDA For TNX-801 As A Potential Vaccine To Prevent Mpox And Smallpox; Phase 1/2 Trial Of TNX-801 To Prevent Mpox, Smallpox to Commence Following Submission Of An IND
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals has announced the results of a pre-IND meeting with the FDA for TNX-801, a potential vaccine to prevent Mpox and Smallpox. Following the submission of an IND, a Phase 1/2 trial of TNX-801 will commence.
August 21, 2023 | 11:17 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tonix Pharmaceuticals' announcement of the pre-IND meeting results with the FDA for TNX-801 and the upcoming Phase 1/2 trial could potentially impact the company's stock positively.
The announcement of the pre-IND meeting results with the FDA for TNX-801, a potential vaccine to prevent Mpox and Smallpox, and the upcoming Phase 1/2 trial is a significant development for Tonix Pharmaceuticals. This could potentially lead to increased investor confidence and a positive impact on the company's stock in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100